BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Sells $350,000.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis sold 10,000 shares of BridgeBio Pharma stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $35.00, for a total value of $350,000.00. Following the completion of the transaction, the director now owns 12,000 shares of the company’s stock, valued at $420,000. This trade represents a 45.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Andrea Ellis also recently made the following trade(s):

• On Tuesday, April 1st, Andrea Ellis sold 30,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $34.05, for a total value of $1,021,500.00.

BridgeBio Pharma Price Performance

BBIO opened at $33.85 on Thursday. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $39.47. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of -11.88 and a beta of 1.08. The business has a 50 day moving average price of $33.69 and a two-hundred day moving average price of $29.95.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. Equities analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. lifted its stake in BridgeBio Pharma by 1.8% during the third quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock valued at $29,155,000 after purchasing an additional 19,978 shares during the last quarter. Teacher Retirement System of Texas lifted its position in shares of BridgeBio Pharma by 28.6% during the 4th quarter. Teacher Retirement System of Texas now owns 36,208 shares of the company’s stock valued at $994,000 after acquiring an additional 8,048 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of BridgeBio Pharma by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock worth $413,738,000 after acquiring an additional 879,059 shares in the last quarter. Exome Asset Management LLC grew its holdings in shares of BridgeBio Pharma by 167.4% in the 3rd quarter. Exome Asset Management LLC now owns 211,000 shares of the company’s stock worth $5,372,000 after acquiring an additional 132,093 shares during the last quarter. Finally, Barclays PLC raised its position in shares of BridgeBio Pharma by 31.9% during the third quarter. Barclays PLC now owns 545,008 shares of the company’s stock worth $13,876,000 after purchasing an additional 131,743 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Analyst Ratings Changes

BBIO has been the subject of a number of research reports. Redburn Atlantic started coverage on BridgeBio Pharma in a research note on Monday, March 31st. They issued a “buy” rating and a $50.00 target price for the company. Evercore ISI increased their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. HC Wainwright boosted their price target on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the company a “buy” rating in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $53.00.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.